NuVasive to acquire Osiris unit

05/8/2008 | Houston Chronicle (tiered subscription model)

NuVasive will purchase Osteocol, a subsidiary of Osiris Therapeutics, in a deal that allows it to gain access to the unit's developing stem cell technology and expand into the biotech market. The acquisition, which will close in the third quarter, includes $35 million in cash and future milestone payments to Osiris worth up to $50 million.

View Full Article in:

Houston Chronicle (tiered subscription model)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
President/Chief Executive Officer
MedCost
Winston-Salem, NC
Consumer Directed Health Plan (CDH) Product Offering Manager
Blue Cross Blue Shield MA
Quincy, MA
Director, Payer Marketing
Avalere Health
Washington, DC
Actuary
Meridian Health Plan
Detroit, MI
Chief Medical Officer, Texas Children's Health Plan
Cejka Executive Search for Texas Childre's Health Plan
Houston, TX